TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?

The Motley Fool Logo The Motley Fool By Reuben Gregg Brewer
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?

Novo Nordisk lost its early lead in the GLP-1 weight loss drug market to Eli Lilly, with its stock down over two-thirds since mid-2024. The article suggests Pfizer, currently facing patent cliffs and a failed internal GLP-1 candidate, may be a better contrarian turnaround play due to lower valuations and aggressive moves to re-enter the GLP-1 space through acquisitions and partnerships.

Insights
NVO   negative

Stock has lost over two-thirds of its value since mid-2024; lost market leadership in GLP-1 space to Eli Lilly; Q3 obesity sales growth of 37% pales in comparison to competitors; positioned as a fading early leader rather than a growth opportunity.